Top stories in endocrinology: Dapaglifozin safe for CV outcomes, liver enzymes foreshadow type 2 diabetes

Among the top stories in endocrinology this week were phase 3 results of dapagliflozin in a CV outcomes trial, a study that concluded liver enzymes foretold type 2 diabetes risk and a report that showed increased use of medications associated with osteoporosis risk.

Additional top stories included a study that found exposure to bisphenol A, or BPA, even at a dose that U.S. regulatory agencies declared safe, may alter change human glucose-stimulated insulin response and findings that some patients with primary aldosteronism undergoing adrenal vein sampling might be exposed to “fairly high” values of excess radiation. – by Janel Miller

Positive CV results reported for dapagliflozin

Results from the phase 3 DECLARE-TIMI 58 cardiovascular outcomes trial confirmed the safety of dapagliflozin, according to a press release from AstraZeneca. Read more.

Liver enzymes predict type 2 diabetes

The development of type 2 diabetes among middle-aged Japanese men is associated with parallel increases in levels of the liver enzymes alanine aminotransferase and gamma-glutamyl transferase, according to findings published in the Journal of Diabetes Investigation. Read more.

Use of medications associated with osteoporosis risk increasing

The use of medications associated with the development of osteoporosis has steadily increased across Denmark in the past 16 years, particularly by those most at risk for fracture, such as postmenopausal women and older adults, according to findings from a registry study published in Bone. Read more.

BPA exposure may alter glucose-stimulated insulin response

Exposure to bisphenol A, or BPA, at a dose deemed safe by U.S. regulatory agencies may change human glucose-stimulated insulin response, according to findings published in the Journal of the Endocrine Society. Read more.

Adrenal vein sampling may expose patients with primary aldosteronism to excess radiation

Patients with primary aldosteronism undergoing adrenal vein sampling to diagnose disease subtype may be exposed to “fairly high” values of excess radiation, but the amount of radiation exposure varies across centers, according to findings published in the European Journal of Endocrinology. Read more.